Vancomycin Utilization Evaluation in a Major Teaching Hospital in West of Iran
Background: Vancomycin is a potent antibiotic and has central role in the managing of infections with known resistance to other antibiotics or in patients with allergy to beta-lactams. Irrational use of vancomycin is associated with increased morbidity and mortality as well as the antibiotic resistant.
Methods: The DUE was done in Imam Reza Hospital, Tabriz, Iran. A total of 100 patients were included during a 6‐month period. We aimed to evaluate vancomycin administration pattern and assess its compliance with Centers for Disease Control and Prevention (CDC) and the American Society of Health-System Pharmacists (ASHP) protocols as the primary outcome and its adverse effects as the secondary outcome.
Results: The mean duration of hospitalization and antibiotic therapy were 22.11 ± 1.76 and 19.08 ± 1.51 respectively (mean ± SD). The most causes of vancomycin administration (51%) were for surgery prophylaxis. In 38% of patients, vancomycin administration was not in accordance to standard guidelines. Dose and duration of vancomycin therapy was according to ASHP and CDC guidelines in 74% and 59% of patients. Dose readjustments of antibiotics were necessary in 28 patients which were done in 12 of them. A total of 140 samples were collected from 60 patients. In 30% of patients, vancomycin use was continued without considering the culture results.
Conclusion: It is important to set practical pharmaceutical and therapeutic infection control committees in hospitals under the clinical pharmacists’ observation. Furthermore, educational programs for health care professionals regarding rational use of antibiotics can be helpful in improving antimicrobial medications utilization and monitoring.
2. Fahimi F, Baniasadi SH, Behzadnia N, Varahram F, Ghazi Tabatabaie L. Enoxaparin Utilization Evaluation: An Observational Prospective Study in Medical Inpatients. Iranian J Pharm Res 2008;7(1):77-82.
3. Stolar MH. Drug use review: operational defenitions. Am J Hosp Pharm 1978;35(1):76-8.
4. Angaran DM. Quality assurance to quality improvement: measuring and monitoring pharmaceutical care. Am J Hosp Pharm 1991;48(9):1901-7.
5. Nightingale J, Chaffe BW, Colvin CL, Alexander MR, Rice T, Ross MB. Retrospective evaluation of vancomycin use in a university hospital. Am J Hosp Pharm 1987;44(8):1807-9.
6. Kaiser AB. Antimicrobial prophylaxis in surgery. N Engl J Med 1986;315(18):1129-38.
7. loannilli A, Sesin P, O’keefe E. Drug Utilization of Vancomycin. J Intraven Nurs 1988;11(4):239-44.
8. Uttley AHC, Collins CH, Naidoo J, George RC. Lancet 1988;1(8575-6):57-8.
9. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase negative staphylococci. N Engl J Med 1987;316(15):927-31.
10. Recommendations for Preventing the Spread of Vancomycin Resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control 1995;23(2):87-94.
11. Phillips MS, Gayman JE, Todd MW. ASHP Guidelines on Medication-Use Evaluation. American Society of Health-system Pharmacists. Am J Health Syst Pharm 1996;53(16):1953-5.
12. Salemi C, Becker L, Morrissey R, Warmington J. A clinical decision process model for evaluating vancomycin use with modified HICPAC guidelines. Hospital Infection Control Practice Advisory Committee. Clin Perform Qual Health Care 1998;6(1):12-6.
13. Evans ME, Kortas KJ. Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines. Infect Control Hosp Epidemiol 1996;17(6):356-9.
14. Fahimi F, Soleymani F, Tavakoli-Ardakani M. Vancomycin Utilization Evaluation in a teaching hospital: A case-series study in Iran. J Pharm Care 2015;1(2):51-4.
15. Vazin A, Japoni A, Shahbazi S, Davarpanah MA. Vancomycin utilization evaluation at hematology-oncology ward of a teaching hospital in Iran. Iran J Pharm Res 2012;11(1):163-70.
16. Hamishehkar H, Ebrahimi D, Mahmoodpoor A, Mashayekhi S, Asgharian P, Reazee H. Drug utilization evaluation of vancomycin in a teaching hospital in Tabriz-Iran. Pharmaceutical Sciences 2015;21(1):25-9.
17. Salehifar E, Babamahmoodi F, Alikhani A, Ganji R, Fazli M. Drug utilization evaluation of vancomycin in a referral infectious center in Mazandaran province. J Pharm Care 2015;2(2):55-9.
18. Khalili H, Gholami KH, Hajiabdolbaghi M, Sairafipoor Z. Vancomycin Drug Utilization Evaluation (DUE) in infectious disease ward of Imam Khomeini Hospital. Tehran University Medical Journal 2006;64(12):64-68.
19. Ayubi M, Elyasi S, Jannati M, et al. Vancomycin utilization evaluation in a tertiary teaching hospital in Mashhad, Iran. J Pharm Care 2017;5(3-4):44-8.
20. Ayazkhoo L, Mousavi S, Ramazani F, Ayatollahi-Tafti M, Sa’dabadi Z, Sistanizad M. Vancomycin utilization evaluation: are we dosing appropriately? J Pharm Care 2015;1(4):149-52.
21. Tavakoli-Ardakani M, Ghassemi S, Alizadeh AM, Salamzadeh J, Ghadiani M, Ghassemi S. Effects of pharmacist intervention on the utilization of vancomycin in a teaching hospital. Iran J Pharm Res 2015;14(4):1281-8.
22. Salemi C, Becker L, Morrissey R, Warmington J. A clinical decision process model for evaluating vancomycin use with modified HICPAC guidelines. Hospital Infection Control Practice Advisory Committee. Clin Perform Qual Health Care 1998;6(1):12-6.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.